跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2017/05/008506
CTRI/2017/05/008506Other未知

A multicenter, open label, multiple-dose, randomized, two-treatment, two period, two-sequence, two-way crossover, steady-state bioequivalence study of Felbamate Oral suspension 600 mg/5 mL of Getz Pharma Research Pvt. Ltd., India with that of FELBATOL® (Felbamate) Oral suspension 600 mg/5 mL of MEDA Pharmaceuticals Inc., Somerset, New Jersey, 08873-4120,USA.,in adult male and non-pregnant female epilepsy (partial seizures with and without generalization) patients already established (run-in) on Felbamate as an monotherapy/adjunctive therapy under fasting condition.

Getz Pharma Research Pvt Ltd0 个研究点目标入组 38 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
未知
状态
Other
入组人数
38
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • •The patients who fulfill all the following inclusion criteria will be included:
  • •i.Patients should be in the range of 18 - 45 years of age (both inclusive).
  • •ii.BMI should be in the range of 18.5 to 24.9 kg/m2
  • •iii.Patients having refractory partial seizures with and without generalization not controlled on standard antiepileptic drugs at therapeutic levels.
  • •iv.Patients with normal findings as determined by baseline history, physical examination and vital signs (seated blood pressure, radial pulse rate, respiratory rate and axillary temperature).
  • •v.Patients with normal / not significant laboratory values as determined by hematological tests, biochemistry, urine analysis, ECG and chest X-ray (P/A view) in correlation with clinical findings.
  • •vi.Willingness to follow the protocol requirement as evidenced by voluntary written informed consent.
  • •vii.Agreeing to, not using or conforming to not having any medication (prescription and over the counter, herbal products), including vitamins and minerals for 15 days prior to study & during the course of the study except any one of Valproic acid, Gabapentin, Levetiracetam or Pregabalin for ongoing therapy of their illness.
  • •viii.No history or presence of significant alcoholism ( > 3 units of alcohol per day) within one year prior to drug administration.
  • •ix.No history of smoking and of drug abuse.
  • •x.All female patients who are of child bearing potential or those within the first two years of the onset of menopausal syndrome using acceptable methods of birth control at least 30 days prior to onset of screening period and till 30 days post last dose of study drug in period-II. Acceptable birth control methods include Barrier methods such as diaphragm/condom with spermicide, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence. Unacceptable methods include oral or implanted or is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the study patient).

排除标准

  • •The patients meeting with any one of the following criteria should be excluded:
  • •i.History of aplastic anemia or hepatic failure.
  • •ii.Requiring medication for any ailment having enzyme-modifying activity in previous one month other than Felbamate, Valproic acid, Gabapentin, Levetiracetam or Pregabalin prior to drug administration day and during the course of the study.
  • •iii.History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological (other than refractory epilepsy), metabolic hematological, gastrointestinal, endocrine or immunological illness.
  • •iv.Participation in any other clinical study within 90 days prior to onset of screening period.
  • •v.History of or currently active malignancy or any other serious diseases.
  • •vi.Any contraindication to blood sampling.
  • •vii.Blood donation within 90 days prior to the commencement of the study.
  • •viii.Patients with positive HIV I/II, HCV tests.
  • •ix.Patients with Positive HBsAg, Positive anti-Hbc and Positive anti HBs.
  • •x.For female patients: Positive serum pregnancy test for female patients.
  • •xi.A history of allergic or adverse reactions to Felbamate, its formulation excipients or any comparable or similar product (carbamates).
  • •xii.A history of severe hepatic impairment, drug induced leucopenia/neutropenia, congenital prolongation of the QT interval, cardiac arrhythmias, myocardial infarction or unstable heart disease
  • •xiii.Concurrent primary psychiatric or neurological diagnosis, including organic mental disorder, severe tardive dyskinesia, or idiopathic Parkinsonâ??s disease.
  • •xiv.Complete blood counts below accepted normal values.
  • •xv.Elevation in liver enzymes, above the normal limits.
  • •xvi.A history of or currently active granulocytopenia or myeloproliferative disorders (drug-induced or idiopathic).
  • •xvii.A medical or surgical condition that might interfere with the absorption, metabolism, or excretion of Felbamate.
  • •xviii.Concurrent use of other drugs known to suppress bone marrow function or causes a significant risk of drug induced hepatitis.
  • •xix.Expected changes in concomitant medications during the period of study.
  • •xx.A history of alcohol or drug dependence by Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria during the 6-month period immediately prior to study entry.
  • •xxi.Not complied with outpatient medication schedule.
  • •xxii.History of multiple syncopal episodes.
  • •xxiii.Lactating or nursing or pregnant female patients or planning to become pregnant during the study.

研究者

相似试验

已完成
不适用
Steady - State Bioequivalence Study of Felbamate Tablets 600 mg (Fasting)
CTRI/2015/06/005925Getz Pharma Research Pvt Ltd38
已完成
1 期
Bioequivalence study comparing felbamate tablets USP 600 mg of Emcure Pharmaceuticals Ltd., India to the Reference Listed Drug (RLD), Felbatol® (felbamate) 600 mg tablets manufactured by MEDA Pharmaceuticals Inc, USA in adult male and nonpregnant female epilepsy patients.
CTRI/2015/08/006138Emcure Pharmaceuticals Ltd28
已完成
不适用
A multi-center, single-dose, open-label, randomized, parallel group study to investigate the reduction of initial taspoglutide Cmax after administration of 20 mg taspoglutide 10% Sustained Release Formulation (SRF) using three modified formulations as compared to the current Phase 3 formulation in healthy volunteers.diabetes mellitus type 210018424diabetes
NL-OMON34034Hoffmann-La Roche100
已完成
不适用
Bioequivalence study of Vigabatrin Tablets 500 mg in refractory complex partial-seizure adult patients on Vigabatrin adjunctive therapy.
CTRI/2020/11/029355Amneal Pharmaceuticals LLC36
进行中（未招募）
不适用
A research study of a new medicine, danoprevir (also known as RO5190591) with ritonavir (also known as NORVIR®) in combination with Pegasys® (also known as PEG-IFN alfa-2a) and Copegus® (also known as ribavirin) for the treatment of a disease called chronic hepatitis C which causes damage to the liver.
EUCTR2010-019584-10-GBF.Hoffmann-La Roche405